Navigation Links
RoundTable Healthcare Partners Facilitates Product Acquisition for CorePharma

Leucovorin Calcium Augments CorePharma's Growing Product Portfolio

LAKE FOREST, Ill., March 16 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company CorePharma LLC ("CorePharma") has completed the acquisition of an ANDA for Leucovorin Calcium tablets. Leucovorin Calcium tablets are the generic equivalent to the Wellcovorin(R) brand previously marketed by Burroughs Wellcome. Leucovorin Calcium tablets are indicated for diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Financial terms of the transaction were not disclosed.

CorePharma is a leading developer and manufacturer of generic, prescription pharmaceutical products. The Company currently has over 30 FDA-approved products on the market with a pipeline of over 25 new products in various stages of development and regulatory approval. CorePharma's diversified product portfolio consists of solid-dose tablets and capsules, and includes modified release dosage form and controlled substance products. The Company's products serve a variety of therapeutic areas and are sold largely through retail channels in the U.S. market. RoundTable acquired a majority interest in CorePharma in 2005.

"The Leucovorin tablet market has long been dominated by generic products," said Christopher J. Worrell, Chief Executive Officer of CorePharma. "With CorePharma's strong marketing capabilities, we have the ability to capture our fair share of the market to return the value envisioned by this transaction."

"Leucovorin Calcium is a well-established chemotherapy adjunct therapy, a valuable product and will be a great addition to CorePharma's growing portfolio," said Jack L. McGinley, a Founding Partner of RoundTable and Chairman of the Board of CorePharma. "We are pleased to continue working with the CorePharma team and executing on our plan of targeting strategic, niche product acquisitions."

About RoundTable Healthcare Partners

RoundTable Healthcare Partners, Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs, and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable currently manages $1.1 billion in capital, including two equity funds totaling $900 million and a subordinated debt fund of $200 million. More information about RoundTable Healthcare Partners and its investments can be found at

SOURCE RoundTable Healthcare Partners
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
2. Media Advisory - Atlantica BioEnergy Task Force Leaders Roundtable
3. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
5. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
6. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
7. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
8. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
9. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):